Revolutionizing dentistry

For the millions of people who stay away from the dentist because they fear the needle and the pain, relief is soon on the way. St. Renatus, LLC plans to introduce the world’s first needle-free dental anesthetic administered through the nasal cavity and suitable for use in procedures involving most of the upper teeth.

Product Development

2000: Patent application filed
2002: Patent approved
2005: FDA Pre-IND meeting
Feb. 2007: Phase 1 safety studies completed
April 2008: Developed improved drug formulation
January 2009: Phase 2 efficacy studies completed
Sept.2009: St. Renatus hires CEO, Steve Merrick
Nov. 2010: FDA Pharmacokinetics (PK) study completed
Dec. 2010: Ipsilateral study completed
March 2011: End of Phase 2 Meeting with FDA
First Half 2011: Estimated start date of Phase 3 FDA clinical studies
Second Half 2011: New Drug Application

Announcements

St. Renatus is pleased to announce the company had a favorable End of Phase 2 review with the FDA on March 3, 2011, and agreed that in the near future, the company will proceed with conducting Phase 3 efficacy studies. Click here for more information.